Comparative Study between the use of Denosumab and Zoledronic acid in Treatment of Giant Cell Tumor of Bone (A Systematic Review and Meta-Analysis)

Abstract

iant cell tumor of bone (GCT) is a locally aggressive osteolytic lesion. It is a rare, generally benign tumor of limb bones that can cause metastases, especially in the lung as well as significant bone destruction. In most cases, GCT occurs in the long bones of skeletally mature adolescents and young adults. The occurrence rate is slightly higher in females than in males. The development of GCT is not clearly understood, and its biological behavior is unpredictable. The available treatment options for GCT involve surgery (intralesional curettage) followed by bone cement packing and/or bone grafting to compensate for resection and restore limb function, with or without adjuvant therapy. Although surgery is the standard treatment, local tumor recurrence rates are high due to the absence of effective adjuvant therapies, and surgery alone can lead to the morbidity of patients. For patients with unsalvageable GCT, radiotherapy with serial embolization is also a treatment option, but malignant transformation may occur after radiation. The present study was a systematic review and meta-analysis for comparing the use of Denosumab and Zoledronic acid in treatment of giant cell tumor of bone and the aim of the study was to review the literature about the use of denosumab